Photocure Future Growth

Future criteria checks 4/6

Photocure is forecast to grow earnings and revenue by 94.9% and 13% per annum respectively. EPS is expected to grow by 94.8% per annum. Return on equity is forecast to be 16.2% in 3 years.

Key information

94.9%

Earnings growth rate

94.8%

EPS growth rate

Pharmaceuticals earnings growth	23.9%
Revenue growth rate	13.0%
Future return on equity	16.2%
Analyst coverage	Low
Last updated	22 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

OTCPK:PHCU.F - Analysts future estimates and past financials data (NOK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	644	72	64	122	2
12/31/2025	545	15	6	37	2
12/31/2024	502	7	38	65	2
9/30/2024	526	14	71	81	N/A
6/30/2024	514	13	41	56	N/A
3/31/2024	512	5	49	63	N/A
12/31/2023	501	1	36	48	N/A
9/30/2023	462	-34	18	29	N/A
6/30/2023	462	-39	36	42	N/A
3/31/2023	418	-62	6	11	N/A
12/31/2022	393	-72	-6	-2	N/A
9/30/2022	383	-79	2	4	N/A
6/30/2022	364	-76	-16	-12	N/A
3/31/2022	354	-68	1	4	N/A
12/31/2021	361	-31	20	24	N/A
9/30/2021	364	7	191	29	N/A
6/30/2021	326	9	12	13	N/A
3/31/2021	290	10	9	11	N/A
12/31/2020	256	-22	14	16	N/A
9/30/2020	274	10	-134	35	N/A
6/30/2020	285	15	53	55	N/A
3/31/2020	284	19	37	39	N/A
12/31/2019	282	32	20	21	N/A
9/30/2019	216	-23	0	1	N/A
6/30/2019	199	-27	-15	-14	N/A
3/31/2019	192	-39	-23	-21	N/A
12/31/2018	182	-37	-26	-24	N/A
9/30/2018	171	-38	-31	-28	N/A
6/30/2018	162	-43	N/A	-26	N/A
3/31/2018	156	-31	N/A	-31	N/A
12/31/2017	151	-35	N/A	-24	N/A
9/30/2017	150	-4	N/A	19	N/A
6/30/2017	149	6	N/A	14	N/A
3/31/2017	145	29	N/A	18	N/A
12/31/2016	144	35	N/A	19	N/A
9/30/2016	140	8	N/A	-33	N/A
6/30/2016	141	3	N/A	-29	N/A
3/31/2016	140	-26	N/A	-18	N/A
12/31/2015	135	-36	N/A	-21	N/A
9/30/2015	126	-58	N/A	-22	N/A
6/30/2015	147	-29	N/A	8	N/A
3/31/2015	138	-23	N/A	1	N/A
12/31/2014	129	-25	N/A	-6	N/A
9/30/2014	129	-2	N/A	-21	N/A
6/30/2014	92	-39	N/A	-64	N/A
3/31/2014	89	-50	N/A	-92	N/A
12/31/2013	84	-59	N/A	-100	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHCU.F's forecast earnings growth (94.9% per year) is above the savings rate (2.6%).

Earnings vs Market: PHCU.F's earnings (94.9% per year) are forecast to grow faster than the US market (15.4% per year).

High Growth Earnings: PHCU.F's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PHCU.F's revenue (13% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: PHCU.F's revenue (13% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PHCU.F's Return on Equity is forecast to be low in 3 years time (16.2%).

Photocure Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Suspends Guidance for 2023

Photocure ASA Provides Revenue Guidance for the Year 2020

Recent updates

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Photocure ASA Announces Change of Board Composition

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies